Phaseline

Targets › RPS2

RPS2 (Small ribosomal subunit protein uS5): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 1 Phase 2, 1 Phase 1; Other, Oncology; next expected readout Jun 2027.

Component of the ribosome, a large ribonucleoprotein complex responsible for the synthesis of proteins in the cell. The small ribosomal subunit (SSU) binds messenger RNAs (mRNAs) and translates the encoded message by selecting cognate aminoacyl-transfer RNA (tRNA) molecules. (UniProt, P15880)

Open in Phaseline: the race on RPS2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Eloxx PharmaceuticalsElx-02
80S Ribosome modulator
RPSA, RPS27, RPS6, RPS2, RPS3Phase 2Alport Syndrome, X-LinkedJun 2027
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)Ataluren
80S Ribosome modulator
RPSA, RPS27, RPS6, RPS2, RPS3Phase 1Colorectal Cancer–

Conditions

Alport Syndrome, X-Linked (1) Colorectal Cancer (1)

Modalities

small molecule (1), antibody (1)

Companies

Eloxx Pharmaceuticals (1) Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1)

Related targets

RPSA (2) RPS27 (2) RPS6 (2) RPS3 (2)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.